Ten years of hormone therapy reduces breast cancer recurrence without compromising quality of life

Bookmark and Share
Published: 5 Jun 2016
Views: 1753
Dr Julie Lemieux - Hôpital du Saint-Sacrement, Québec, Canada

Dr Lemieux presents at ASCO 2016, a randomised phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole from 5 to 10 years.

Read the news story or watch the video interview for more.